Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Wratchford

Internal Medicine Mechanicsville, VA Medical Doctor

NPI 1265498422 CMS profile 330129

7493 Right Flank Rd, Suite 400, Mechanicsville, VA 23116

Open in the dashboard

General payments

$9,505

614 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Wratchford of Mechanicsville, VA is reported in the CMS Open Payments database as having received $9,505 across 614 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,466 90
2024 General $1,698 97
2023 General $1,461 90
2022 General $1,426 87
2021 General $1,342 103
2020 General $980 66
2019 General $1,131 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Wratchford
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Timothy Wratchford were reported at $1,466. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Timothy Wratchford Internal Medicine median Middle half National median
2019 $1,131 $159 $48–$570 $163
2020 $980 $119 $33–$402 $114
2021 $1,342 $135 $37–$521 $132
2022 $1,426 $141 $42–$496 $149
2023 $1,461 $149 $45–$519 $160
2024 $1,698 $154 $47–$537 $164
2025 $1,466 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,198 105 payments
  2. AbbVie, Inc. $997 86 payments
  3. AstraZeneca Pharmaceuticals LP $763 42 payments
  4. Lilly USA, LLC $737 43 payments
  5. Amgen Inc. $649 46 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $569 35 payments
  7. Pfizer Inc. $519 30 payments
  8. GlaxoSmithKline, LLC. $421 27 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $283 16 payments
  10. Otsuka America Pharmaceutical, Inc. $173 9 payments
  11. Other $3,196 175 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,443 611 payments
  2. Education $62 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $798 73 payments
  2. RYBELSUS $660 61 payments
  3. UBRELVY $457 40 payments
  4. TRINTELLIX $444 25 payments
  5. NURTEC ODT $379 19 payments
  6. QULIPTA $350 31 payments
  7. FARXIGA $304 13 payments
  8. ZAVZPRET $292 16 payments
  9. SHINGRIX $291 17 payments
  10. BREZTRI $284 14 payments
  11. Other $9,306 574 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 112 drugs

Part D claims

4,519

Median for Internal Medicine: 777

Drug cost

$245,621

Median for Internal Medicine: $73,373

Branded share of claims

21.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 36 $37,738
Mounjaro Tirzepatide Brand 21 $32,469
Eliquis Apixaban Brand 43 $28,828
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $20,774
Januvia Sitagliptin Phosphate Brand 23 $14,567
Repatha Sureclick Evolocumab Brand 17 $12,704
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 23 $12,660
Jardiance Empagliflozin Brand 16 $10,371
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $8,280
Levemir Flexpen Insulin Detemir Brand 15 $4,540

The 10 drugs with the highest cost, of 112 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$81,841

Of which drugs: $7,761

Medicare patients

314

Average age 73

Services billed

6,594

122 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 39%
Ischemic heart disease 22%
Diabetes 21%
Cancer 16%
Atrial fibrillation 14%
Chronic kidney disease 11%
Depression 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 60 60 $4,880
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 960 $99

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $78
  • Otsuka America Pharmaceutical, Inc. $54
$132 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $109
$109 — —
NURTEC ODT
  • PFIZER INC. $74
$74 — —
ZAVZPRET
  • PFIZER INC. $74
$74 — —
UBRELVY
  • AbbVie, Inc. $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

614 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record